Scambia G, Masciullo V, Benedetti Panici P, Marone M, Ferrandina G, Todaro N, Bellacosa A, Jain S K, Neri G, Piffanelli A, Mancuso S
Department of Gynecology and Obstetrics, Catholic University, Rome, Italy.
Br J Cancer. 1997;75(10):1547-53. doi: 10.1038/bjc.1997.264.
Ras/p21 oncoprotein expression and K-ras mutations were analysed by Western blot and/or K-ras oligonucleotide hybridization in 78 primary ovarian cancers, 20 omental metastases, two low malignant potential tumours (LMP), nine benign ovarian tumours and 10 normal ovaries. A cut-off value of an integral of absorbance (i.a.) of 2.20, obtained by receiver operating characteristic (ROC) curve, was shown to be the best cut-off for defining p21 positivity. p21 levels were higher in malignant tumours than in benign tumours (median 2.10 i.a. vs median 1.22 i.a.; P = 0.014) and in omental metastases than in primary ovarian carcinomas (median 2.54 i.a. vs median 2.1 i.a.; P = 0.0089). p21 overexpression did not correlate with any of the clinicopathological parameters examined. Follow-up data were available for 63 patients. A significant relationship was shown between p21 positivity and a shorter overall survival (OS) (P < 0.03) and progression-free survival (PFS) (P < 0.03). In multivariate analysis only the presence of ascites, p21 levels and epidermal growth factor receptor status retained an independent prognostic role. K-ras gene mutations were frequently detected in benign and low malignant potential tumours (71.4%), which were mostly mucinous (P = 0.0152).
通过蛋白质免疫印迹法和/或K-ras寡核苷酸杂交技术，对78例原发性卵巢癌、20例网膜转移瘤、2例低度恶性潜能肿瘤（LMP）、9例良性卵巢肿瘤和10例正常卵巢组织进行Ras/p21癌蛋白表达及K-ras突变分析。通过受试者工作特征（ROC）曲线得出吸光度积分（i.a.）的截断值为2.20，该值被证明是定义p21阳性的最佳截断值。恶性肿瘤中的p21水平高于良性肿瘤（中位数2.10 i.a. 对中位数1.22 i.a.；P = 0.014），网膜转移瘤中的p21水平高于原发性卵巢癌（中位数2.54 i.a. 对中位数2.1 i.a.；P = 0.0089）。p21过表达与所检测的任何临床病理参数均无相关性。63例患者有随访数据。p21阳性与较短的总生存期（OS）（P < 0.03）和无进展生存期（PFS）（P < 0.03）之间存在显著相关性。多因素分析显示，只有腹水的存在、p21水平和表皮生长因子受体状态保留独立的预后作用。K-ras基因突变在良性和低度恶性潜能肿瘤中频繁检测到（71.4%），这些肿瘤大多为黏液性（P = 0.0152）。
